OncoMatch

OncoMatch/Clinical Trials/NCT05949944

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

Is NCT05949944 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Linperlisib in combination with CHOP for peripheral t-cell lymphoma.

Phase 1/2RecruitingSun Yat-sen UniversityNCT05949944Data as of May 2026

Treatment: Linperlisib in combination with CHOPThis phase Ib/II, single arm, open label, multicenter study is conducted to evaluate the efficacy and safety of linperlisib in combination with CHOP for newly diagnosed PTCL patients, and explore the reasonable dosage of linperlisib when combined with CHOP regimen.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: PI3K inhibitor

Received PI3K inhibitor treatment before enrollment

Lab requirements

Blood counts

Adequate bone marrow function required

Kidney function

No renal failure requiring hemodialysis or peritoneal dialysis

Liver function

No decompensated cirrhosis (Child Pugh B or C); no clinically significant liver disease; viral hepatitis B and C must be controlled as specified

Cardiac function

No ≥ Level 2 myocardial ischemia or infarction, arrhythmia (including QTc ≥ 450ms (male), QTc ≥ 470ms (female)), or ≥ Level 2 congestive heart failure (NYHA classification)

Adequate bone marrow and organ functions; Poor blood pressure control (systolic blood pressure ≥ 150mm Hg or diastolic blood pressure ≥ 100 mmHg); ≥ Level 2 myocardial ischemia or infarction, arrhythmia (including QTc ≥ 450ms (male), QTc ≥ 470ms (female)), and ≥ Level 2 congestive heart failure (NYHA classification); Active interstitial pneumonia or other chronic lung diseases, leading to severe impairment of lung function, defined as FEV1 and DLCOc<60% of normal predicted values; Decompensated cirrhosis (Child Pugh liver function rating of B or C); Known clinically significant history of liver disease; Renal failure requiring hemodialysis or Peritoneal dialysis

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify